Ann: Corporate Presentation, page-13

Yes, sector comparables are on much higher multiples. That's why I'm looking at IME. I think the fact that all of their current revenue is coming from South America would be a factor contributing to that. Less developed markets.

I did a comparison between the two investor presentations and there have been a couple of other changes:

Reference to 100% retention of SAAS customers has been deleted.

Delays to expansions in all new markets and delay in estimated FDA approval in US. New estimates are 3-6months delayed from previous estimates.